secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-168569
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB BIO reports positive Phase 1 SAB-142 data: C-peptide preservation, T cell exhaustion, improved glycemic control
--------------------------------------------------------------------------------

- All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.
- SAB-142 induced CD4+ Tconv cell exhaustion (TIGIT+ levels) correlating with C-peptide preservation, consistent with rabbit ATG mechanism.
- Mean CGM time in range improved from 73% at baseline to 85% at Day 120, with no increase in exogenous insulin use.
- Phase 2b SAFEGUARD trial topline data expected in 2H 2027; CEO cites potential best-in-class profile for T1D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526168569/0001193125-26-168569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526168569/sabs-20260422.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-168569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer